Cannabis terapeutica, dopo Milano arriva l’appello del Piemonte

In Piemonte, nell’ultimo anno, è triplicato il numero di pazienti trattati con medicinali a base di cannabis e il numero delle prescrizioni è cresciuto di oltre cinque volte.

l’assessore regionale alla Sanità Antonio Saitta.

“I dati ci dicono che c’è una richiesta crescente da parte dei pazienti e c’è un aumento delle prescrizioni da parte dei medici di cannabis ad uso medico”, spiega in una nota l’assessore regionale alla Sanità Antonio Saitta.“Purtroppo non sempre lo Stabilimento chimico farmaceutico militare di Firenze, l’unico autorizzato per legge alla fornitura, riesce a soddisfare tempestivamente tutte le richieste. Chiediamo dunque al Ministero della Salute, secondo quanto prevede la norma, di individuare e autorizzare altri enti alla produzione dei farmaci”.

Un problema che si sta riscontrando un po’ ovunque, tanto che, per esempio, il consiglio comunale di Milano ha approvato una mozione che invita il Comune a prendere in considerazione la possibilità di avviare una coltivazione controllata di cannabis terapeutica nel Parco Sud e nelle tante cascine limitrofe alla città. Una scelta, come abbiamo già avuto modo di sottolineare, che avrebbe molteplici benefici: per i pazienti, che non avrebbero problemi di mancanza di scorte, e per il sistema Paese, che potrebbe favorire la crescita economica di un settore che offrirebbe molti sbocchi anche dal punto di vista dei posti di lavoro.
La cannabis ad uso medico, che in Piemonte è stata regolamentata con una legge approvata dal Consiglio regionale nel 2015, può essere impiegata per sei aree di patologie e soltanto quando le terapie tradizionali si sono rivelate inefficaci. A Torino e nelle altre province piemontesi, oltre il 70% dei trattamenti riguarda analgesia nel dolore cronico o neurogeno.

In dettaglio, nel corso del 2017 i malati trattati con cannabis ad uso terapeutico sono stati 639 (con un incremento rispetto al 2016 pari al 205,74%) per un totale di 2.683 prescrizioni. Di queste, 770 sono state effettuate da medici di medicina generale (28,70%) e 1.913 da medici specialisti (71,30%). Nel 2016 erano stati 209 per un totale di 483 prescrizioni.

La spesa totale registrata in Regione Piemonte nel 2017 per tali preparati è stata di 193.089 euro, con un incremento del 107,07% rispetto al 2016.

 

 

https://beleafmagazine.it/2018/10/09/cannabis-terapeutica-dopo-milano-arriva-lappello-del-piemonte/

Courts are beginning to rule against employers who discriminate against medical marijuana users

Risultati immagini per Katelin NoffsingerHealth care worker Katelin Noffsinger told a potential employer that she took medical marijuana to deal with the effects of a car accident, but when a drug test came back positive, the nursing home rescinded her job offer anyway. A federal judge last month ruled that the nursing home, which had cited federal laws against pot use, violated an anti-discrimination provision of the Connecticut’s medical marijuana law. It was the latest in a series of clashes between U.S. and state laws around the country that came out in favor of medical marijuana users trying to keep or obtain jobs with drug-testing employers.

Sorgente: Courts are beginning to rule against employers who discriminate against medical marijuana users

L’Onu in difesa dei coltivatori di cannabis. Che sia la volta buona?

Un altro colpo all’antiproibizionismo ideologico? Sembrerebbe proprio di sì, dato che le Nazioni Unite hanno adottato una dichiarazione che invita unitamente tutti i Paesi a “rispettare e proteggere le necessità rurali”, puntando a “incentivare le politiche agricole che comprendono la Cannabis nelle loro strategie di sviluppo“.

La Dichiarazione sui Diritti dei Contadini e di altri Lavoratori nelle Aree Rurali ha lo scopo di spostare le discussioni relative a tematiche connesse alla Cannabis fuori da una logica superata per la quale si tratta solo di ‘approccio e forma mentis avverse alla agli aspetti narcotici’, secondo quanto riportato da un testo ufficiale FAAAT (For Alternative Approaches to Addiction), un gruppo di discussione ed approfondimento nella forma di think tank.

La Dichiarazione nello specifico, punta a guidare le politiche dello sviluppo delle Nazioni con una ricca storia nella coltivazione della Cannabis, come Marocco, Sud Africa e India dove i produttori locali sono stati tra i principali coltivatori a livello mondiale ed hanno sofferto in modo variamente sproporzionato i vari divieti e proibizioni nel contesto globale. Persino il Programma di Sviluppo delle Nazioni Unite ha dovuto riconoscere che i gruppi vulnerabili come i contadini sono quelli che più hanno sofferto di questa manifesta e mondiale disparità di trattamento.

La nota ufficiale FAAAT recita: “Il diritto a coltivare piante di Cannabis nelle aree dove la sua coltivazione è da considerarsi persino ancestrale nel tempo è riconosciuto da differenti testi internazionali che proteggono le tradizioni indigene dei popoli”.

La Dichiarazione nello specifico, punta a guidare le politiche dello sviluppo delle Nazioni con una ricca storia nella coltivazione della Cannabis, come Marocco, Sud Africa e India dove i produttori locali sono stati tra i principali coltivatori a livello mondiale ed hanno sofferto in modo variamente sproporzionato i vari divieti e proibizioni nel contesto globale. Persino il Programma di Sviluppo delle Nazioni Unite ha dovuto riconoscere che i gruppi vulnerabili come i contadini sono quelli che più hanno sofferto di questa manifesta e mondiale disparità di trattamento.

La nota ufficiale FAAAT recita: “Il diritto a coltivare piante di Cannabis nelle aree dove la sua coltivazione è da considerarsi persino ancestrale nel tempo è riconosciuto da differenti testi internazionali che proteggono le tradizioni indigene dei popoli”.

Questa Dichiarazione ONU giunge in anticipazione dei lavori che si terranno nell’ambito dellaConferenza Internazionale sulle Politiche della Cannabis che si terrà a Vienna l’8 e il 9 Dicembre. Questa Conferenza rappresenta il meeting finale globale prima della Sessione sulle politiche sulle droghe del prossimo Marzo durante il quale è in lista di discussione e definizione il Trattato sulla Canapa ed un piano d’azione 2019-2029 che sarà poi votato dalle rispettive Nazioni.

https://beleafmagazine.it/2018/10/06/lonu-in-difesa-dei-coltivatori-di-cannabis-che-sia-la-volta-buona/

Hungarian bioengineering giant developing cannabinoid production process

Hungarian biotech giant is using an engineered yeast strain to “brew” cannabinoids via fermentation.

The extraction of cannabinoids from cannabis plants is a huge and growing industry. From edibles to portable vape cartridges, cannabinoid extraction makes all kinds of products possible. There are several different methods of extracting cannabinoids from the plant. But all of them are resource-intensive processes requiring large quantities of raw cannabis.

But what if it were possible to extract cannabinoids without growing cannabis plants at all? That’s exactly the idea behind a breakthrough innovation from the bioengineering firm Intrexon Corporation. Today, the company announced it had made major strides in its project to produce cannabinoids with yeast.

Biotech Firm Wants to “Brew” Weed with Yeast

Intrexon Corporation is a Hungarian bioengineering giant based in Budapest. Through a synthetic biology approach they call “Better DNA,” Intrexon creates biologically-based products for industries. They work with companies to design and develop complex biological systems that improve the quality and performance of living cells. And the company wants to develop technologies to produce cannabinoids for the medical cannabis industry.

But Intrexon isn’t developing a new strain of cannabis or a new way of extracting cannabinoids from marijuana plants. Instead, they’re using the single-cell microorganisms of the genus saccharomyces, or yeast.

Intrexon says it has bioengineered a strain of yeast that produces cannabinoids for medical uses, like CBDTHCV, and others. In other words, the company is using the tiny microbes to actually make cannabinoids, rather than extract them from cannabis plants.

The process involves fermentation. So, in essence, Intrexon is “brewing” cannabinoids with a proprietary strain of microbes it developed. Furthermore, Intrexon says their DNA-engineered yeast strain is versatile enough to produce different cannabinoids. These include cannabinoids with high therapeutic indexes but that only exist in trace amounts in the plant, making their commercial extraction too costly. The process could also synthesize new, “designer” cannabinoids.

Will Biotech Make Growing Cannabis Irrelevant

Of course, Intrexon says their cannabinoid-producing yeast has several advantages over plant-based extraction. In addition to cost savings and reducing resource consumption, the company says their microbial platform can be tailored to the production of specific target cannabinoids. “Through our capabilities and experience, we expect to optimize [yeast] strains to produce specific cannabinoids that may be commercialized in the coming years,” said  Chris Savile,

Chris Savile

PhD, Executive Director of Commercial Operations at Intrexon.

And today, the company marked an important milestone on the road toward that vision. According to a press release, Intrexon is closer than ever to reaching its goal of producing pure cannabinoids at under $1,000 per kilogram. The announcement has sent Intrexon shares (NYSE:XON) skyrocketing nearly 30 percent today.

While bioengineering cannabinoids may sound like something out of speculative fiction, more biotech firms are working on ways to produce what’s valuable about cannabis without growing the plants themselves. The Boston-based biotech firm Gingko Bioworks, Inc. recently announced its plans to produce rare cannabinoids directly from plant DNA.

As many cannabis cultivators have experienced, extreme weather events, fires, regulatory changes and many other factors can impact cannabis farmers’ bottom line. Plus, the medical cannabis industry continues demanding more exacting standards from cannabis products. Hence, eliminating the need to actually grow cannabis plants is fast-becoming an attractive prospect for some in the industry.

 

 

 

 

https://420intel.com/articles/2018/09/25/hungarian-bioengineering-giant-developing-cannabinoid-production-process?utm_source=420+Intel+-+Marijuana+Industry+News&utm_campaign=cc872c1129-420+Intel&utm_medium=email&utm_term=0_3210cbef52-cc872c1129-270890321

Cannabis analgesia in chronic neuropathic pain is associated with altered brain connectivity.

OBJECTIVE:
To characterize the functional brain changes involved in δ-9-tetrahydrocannabinol (THC) modulation of chronic neuropathic pain.

METHODS:
Fifteen patients with chronic radicular neuropathic pain participated in a randomized, double-blind, placebo-controlled trial employing a counterbalanced, within-subjects design. Pain assessments and functional resting state brain scans were performed at baseline and after sublingual THC administration. We examined functional connectivity of the anterior cingulate cortex (ACC) and pain-related network dynamics using graph theory measures.

RESULTS:
THC significantly reduced patients’ pain compared to placebo. THC-induced analgesia was correlated with a reduction in functional connectivity between the anterior cingulate cortex (ACC) and the sensorimotor cortex. Moreover, the degree of reduction was predictive of the response to THC. Graph theory analyses of local measures demonstrated reduction in network connectivity in areas involved in pain processing, and specifically in the dorsolateral prefrontal cortex (DLPFC), which were correlated with individual pain reduction.

CONCLUSION:
These results suggest that the ACC and DLPFC, 2 major cognitive-emotional modulation areas, and their connections to somatosensory areas, are functionally involved in the analgesic effect of THC in chronic pain. This effect may therefore be mediated through induction of functional disconnection between regulatory high-order affective regions and the sensorimotor cortex. Moreover, baseline functional connectivity between these brain areas may serve as a predictor for the extent of pain relief induced by THC.
© 2018 American Academy of Neurology.

 

 

 

https://www.ncbi.nlm.nih.gov/pubmed/30185448

House Rules Committee Blocks FY19 Marijuana Amendments

My first amendment, cosponsored by Representatives Dana Rohrabacher, Barbara Lee and Earl Blumenauer, strikes the rider that prohibits D.C. from spending its local funds to commercialize recreational marijuana.  Nine states have legalized recreational marijuana, and eight of those states have approved commercialization.

In February 2015, D.C. legalized the possession of marijuana for recreational use, after two independent studies found dramatic racial disparities in marijuana arrests in D.C.  A rider to block recreational use failed due to faulty drafting, and possession of up to two ounces of marijuana for recreational use is legal in D.C., but Congress has prohibited D.C. from spending its local funds to tax and regulate recreational marijuana.  This rider has unintentionally benefited violent drug gangs.  For that reason, some refer to it as the “Drug Dealer Protection Act.”  As one marijuana dealer told the Washington Post, the rider is “a license for me to print money.”  Regulating marijuana like alcohol would allow D.C., instead of drug dealers, to control production, distribution, sales and revenues.

 

Sorgente: House Rules Committee Blocks FY19 Marijuana Amendments

Oklahoma: Voters Decide In Favor Of Statewide Medical Cannabis Access Law

A majority of Oklahomans today voted to enact State Question 788 — a statewide voter-initiated measure that permits doctors to use their discretion to recommend medical cannabis to those patients who will benefit from it. Oklahoma is now the 31st state to legalize and regulate the use of medical cannabis under state law.

“Public support for medical marijuana access is non-partisan,” NORML Deputy Director Paul Armentano said. “Even in a predominantly ‘red’ state like Oklahoma, it is the will of the voters to enact common sense, yet significant marijuana law reforms.”

He continued, “The ongoing expansion of compassionate medical marijuana in states like Oklahoma places additional pressure upon Congress to take action to end this existing state/federal conflict. It is time for members to move forward with legislation like The States Act or The Ending Federal Marijuana Prohibition Act, which would allow states the flexibility and autonomy to regulate cannabis as best they see fit — free from the looming threat of undue federal intervention.”

 

Sorgente: Oklahoma: Voters Decide In Favor Of Statewide Medical Cannabis Access Law

Weekly Legislative Roundup 6/15/18

A lot has happened in Congress this week. US Senate Majority Leader Mitch McConnell (R-KY) succeeded in inserting hemp legalization language into the wide-ranging Farm Bill – must-pass legislation that is approved by Congress every five years. The bill was then approved by the US Senate Agriculture, Nutrition and Forestry Committee.

The US Senate Appropriations Committee, for the first time ever, included protections for state medical marijuana laws in base Justice Department funding legislation. On the other hand, the US House Appropriations Committee rejected an amendment to protect banks that work with marijuana businesses from being punished by federal authorities.

Congresswoman Barbara Lee introduced The “RESPECT Resolution: Realizing Equitable & Sustainable Participation in Emerging Cannabis Trades” to elevate the importance of equity within the legal cannabis marketplace.

To all of our surprise, President Donald Trump expressed verbal support for recently introduced, bi-partisan legislation that seeks to codify legal protections for state-sanctioned marijuana-related activities. Similarly, members of the Congressional Black Caucus recently announced their support for marijuana law reforms to keep the federal government out of the business of prohibition and related law enforcement of marijuana.

At the state level, South Carolina voters approved a medical marijuana advisory question on the Democratic primary ballot by a margin of 81% – 19%. And The Maine Supreme Court ruled that employers don’t need to pay for medical cannabis under the state workers’ compensation system.

At a more local level, the St. Louis, Missouri circuit attorney will no longer pursue cases for marijuana in the amount of less than 100 grams. And Denver, Colorado is using marijuana tax revenue to fund after-school and summer programs.

Sorgente: Weekly Legislative Roundup 6/15/18